MedTrace Logo

Expanded Access to ANG1005 for Individual Patients

NCT02755987 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2016-06-07

No results posted yet for this study

Summary

This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1005-CLN-04 with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.

Conditions

  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • Breast Cancer With Recurrent Brain Metastases
  • Leptomeningeal Carcinomatosis

Interventions

DRUG

ANG1005

Sponsors & Collaborators

  • Angiochem Inc

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02755987 on ClinicalTrials.gov